These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 29178442)
21. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants. Wu J; Gießmann T; Lang B; Elgadi M; Huang F J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158 [TBL] [Abstract][Full Text] [Related]
22. Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. Harvey RD; Aransay NR; Isambert N; Lee JS; Arkenau T; Vansteenkiste J; Dickinson PA; Bui K; Weilert D; So K; Thomas K; Vishwanathan K Br J Clin Pharmacol; 2018 Dec; 84(12):2877-2888. PubMed ID: 30171779 [TBL] [Abstract][Full Text] [Related]
23. Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. Matsunashi A; Fujimoto D; Hosoya K; Irie K; Fukushima S; Tomii K Invest New Drugs; 2020 Aug; 38(4):1192-1195. PubMed ID: 31486987 [TBL] [Abstract][Full Text] [Related]
24. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects. Groenendaal-van de Meent D; den Adel M; van Dijk J; Barroso-Fernandez B; El Galta R; Golor G; Schaddelee M Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):685-692. PubMed ID: 29752643 [TBL] [Abstract][Full Text] [Related]
25. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects. Disanto AR; Golden G Clin Drug Investig; 2009; 29(8):539-49. PubMed ID: 19591515 [TBL] [Abstract][Full Text] [Related]
26. Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects. Small DS; Royalty J; Cannady EA; Hale C; Wang MD; Downs D; Suico JG Pharmacotherapy; 2016 Jul; 36(7):749-56. PubMed ID: 27284735 [TBL] [Abstract][Full Text] [Related]
27. The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects. Cao B; Ma T; Zhang Y; Huang L; Lin H; Jiang H; Zhao Y; Geng Y; Yang Y; Cao S; Li J Invest New Drugs; 2024 Jun; 42(3):289-298. PubMed ID: 38602625 [TBL] [Abstract][Full Text] [Related]
28. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. Hsyu PH; Pignataro DS; Matschke K Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000 [TBL] [Abstract][Full Text] [Related]
29. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795 [TBL] [Abstract][Full Text] [Related]
31. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food. Zomorodi K; Kankam M; Lu Y Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686 [TBL] [Abstract][Full Text] [Related]
33. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects. Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164 [TBL] [Abstract][Full Text] [Related]
34. Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer. Vishwanathan K; Cantarini M; So K; Masson E; Fetterolf J; Ramalingam SS; Harvey RD Clin Transl Sci; 2020 Jan; 13(1):41-46. PubMed ID: 31498564 [TBL] [Abstract][Full Text] [Related]
35. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396 [TBL] [Abstract][Full Text] [Related]
36. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. Yu HA; Schoenfeld AJ; Makhnin A; Kim R; Rizvi H; Tsui D; Falcon C; Houck-Loomis B; Meng F; Yang JL; Tobi Y; Heller G; Ahn L; Hayes SA; Young RJ; Arcila ME; Berger M; Chaft JE; Ladanyi M; Riely GJ; Kris MG JAMA Oncol; 2020 Jul; 6(7):1048-1054. PubMed ID: 32463456 [TBL] [Abstract][Full Text] [Related]
37. Absolute Bioavailability of Osimertinib in Healthy Adults. Vishwanathan K; So K; Thomas K; Bramley A; English S; Collier J Clin Pharmacol Drug Dev; 2019 Feb; 8(2):198-207. PubMed ID: 29683562 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885 [TBL] [Abstract][Full Text] [Related]
39. A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults. Pierce D; Corcoran M; Velinova M; Hossack S; Hoppenbrouwers M; Martin P Drug Des Devel Ther; 2015; 9():1257-68. PubMed ID: 25767373 [TBL] [Abstract][Full Text] [Related]
40. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]